Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00286637 · ClinicalTrials.gov registry record

Novel Glaucoma Diagnostics

A clinical trial of Glaucoma and Macular Disease, sponsored by Wills Eye.

Recruiting
Registry status
5,000
Enrollment target
1
Study location

NCT00286637 is a study of Glaucoma and Macular Disease that is actively recruiting participants, run by Wills Eye. The registered enrollment target is 5,000 participants, above the 856-participant average among 92 other Glaucoma trials with a reported enrollment target (484% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00286637, a study of Glaucoma and Macular Disease, is actively recruiting participants, sponsored by Wills Eye.

RECRUITING
Registry status
5,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Conditions Studied

Study Locations (1)

Pennsylvania

  • Wills Eye Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2000-08-01
Est. Completion 2029-07-31

Sponsor

Wills Eye

59 total trials

What the Registry Record Tells You About NCT00286637

The ClinicalTrials.gov registry entry for NCT00286637 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 856-participant average among 92 other Glaucoma trials with a reported enrollment target (484% higher). The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 0 interventions.

NCT00286637 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00286637 about?

NCT00286637 is a clinical study titled "Novel Glaucoma Diagnostics". The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measu...

What is the current status of trial NCT00286637?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2000-08-01. Estimated completion is 2029-07-31.

What conditions does trial NCT00286637 study?

This clinical trial studies the following conditions: Glaucoma, Macular Disease.

Who is sponsoring clinical trial NCT00286637?

This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00286637 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.